BioCentury | Feb 19, 2007
Strategy

Outsourcing from Japan

While a growing number of companies in the West are moving at least some of their R&D activities to Asia, Atlas Venture and a group of Japanese investors are thinking in the reverse direction. Shogoo...
BC Extra | Feb 3, 2007
Financial News

Shogoo raises $13.2 million

Infectious disease company Shogoo Pharmaceuticals (Tokyo, Japan) raised Y1.6 billion ($13.2 million) in a series A round led by Atlas Venture; NIF SMBC Ventures; and new investor Nomura R&A. Shogoo's lead compound is SPK-0601, a...
BC Week In Review | Aug 28, 2006
Company News

Shogoo Pharmaceuticals K.K infectious news

Shogoo formed Shogoo Pharmaceuticals AG, a wholly owned subsidiary located in Basel, Switzerland. Rudolf Meyer, chairman of consulting firm InterPharmaLink AG, will be CEO of the subsidiary. The Swiss unit will have global rights to...
BC Extra | Aug 22, 2006
Company News

Shogoo forms Swiss subsidiary

Shogoo (Tokyo, Japan) formed Shogoo Pharmaceuticals AG, a wholly owned subsidiary located in Basel. Rudolf Meyer, chairman of consulting firm InterPharmaLink, will be CEO of the subsidiary. The Swiss unit will have global rights to...
BC Week In Review | Feb 13, 2006
Company News

BioSphings AG, Shogoo deal

Shogoo acquired exclusive worldwide rights to develop and commercialize BioSphing's SPK-0601, which is in preclinical development to treat diseases caused by viral infection. Financial terms were not disclosed. The small molecule inhibits viral gene expression...
Items per page:
1 - 5 of 5
BioCentury | Feb 19, 2007
Strategy

Outsourcing from Japan

While a growing number of companies in the West are moving at least some of their R&D activities to Asia, Atlas Venture and a group of Japanese investors are thinking in the reverse direction. Shogoo...
BC Extra | Feb 3, 2007
Financial News

Shogoo raises $13.2 million

Infectious disease company Shogoo Pharmaceuticals (Tokyo, Japan) raised Y1.6 billion ($13.2 million) in a series A round led by Atlas Venture; NIF SMBC Ventures; and new investor Nomura R&A. Shogoo's lead compound is SPK-0601, a...
BC Week In Review | Aug 28, 2006
Company News

Shogoo Pharmaceuticals K.K infectious news

Shogoo formed Shogoo Pharmaceuticals AG, a wholly owned subsidiary located in Basel, Switzerland. Rudolf Meyer, chairman of consulting firm InterPharmaLink AG, will be CEO of the subsidiary. The Swiss unit will have global rights to...
BC Extra | Aug 22, 2006
Company News

Shogoo forms Swiss subsidiary

Shogoo (Tokyo, Japan) formed Shogoo Pharmaceuticals AG, a wholly owned subsidiary located in Basel. Rudolf Meyer, chairman of consulting firm InterPharmaLink, will be CEO of the subsidiary. The Swiss unit will have global rights to...
BC Week In Review | Feb 13, 2006
Company News

BioSphings AG, Shogoo deal

Shogoo acquired exclusive worldwide rights to develop and commercialize BioSphing's SPK-0601, which is in preclinical development to treat diseases caused by viral infection. Financial terms were not disclosed. The small molecule inhibits viral gene expression...
Items per page:
1 - 5 of 5